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Background: Although bevacizumab has deleterious effects on the healing of colonic anastomoses,
trapidil improves wound healing of colonic and tracheal anastomoses.Key words:
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Objective: We aimed to assess the effects of bevacizumab and trapidil on wound healing after tracheal
transection.
Materials and methods: We evaluated 35 rats divided in 5 groups: bevacizumab (Group I, n ¼ 7), trapidil
(Group II, n ¼ 7), trapidil þ bevacizumab (Group III, n ¼ 7), controls (Group IV, n ¼ 7), and sham (Group V,
n ¼ 7). Anastomotic healing was assessed by measurement of bursting pressure and inﬂammation score at
the anastomotic region on the seventh day.
Results: The bursting pressures of Group II, Group III, and Group V were signiﬁcantly higher than controls
(P ¼ 0.001, P ¼ 0.033, and P ¼ 0.035, respectively). Fibrosis was signiﬁcantly high in the sham group when
compared with the other four groups (P ¼ 0.047).
Conclusions: Although bevacizumab seems to impair anastomotic healing, trapidil can be suggested to
improve tracheal anastomoses.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Bevacizumab has become the standard therapy in a variety of
solid tumors, including colorectal, kidney, gliablastome multi-
forme, and lung cancer.1–3 Many studies have demonstrated
deleterious effects of agent targeting vascular endothelial growth
factor on the healing of colonic anastomoses. Vascular endothelial
growth factor-targeted therapies inhibit nitric oxide synthetase. By
this way the release of nitric oxide will decrease.3
Trapidil is an antiplatelet agent that acts in part as a phosphodies-
terase inhibitor and as a competitive inhibitor of the platelet-derived
growth factor receptor. Trapidil, with its vasodilator and nitric oxide-
releasing effects, may have some potential to diminish tissue injury.4r Inc.
nlikkoy M. Sehit Muammer
rkey.
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Open access under CC BY license.In our study, we aimed to investigate the effects of bevacizu-
mab and trapidil on wound healing after tracheal transection.Materials and Methods
The study was approved by the Ethics Committe of Mersin
University (No. 2011/04). The study was carried out at the
Laboratory Animals of Mersin University. The animals were main-
tained in accordance with guidelines of the Committe on Care and
Use of Mersin University Medical Faculty Animal Research
Laboratory.
Thirty-ﬁve Wistar albino rats weighting 250 to 300 g were
divided into 5 groups: Group I, single-dose bevacizumabn
5 mg/kg (1) intraperitoneally (n ¼ 7); Group II, 12 mg/kg
(1)/day trapidil† orally 1 week (n ¼ 7); Group III, single-
dose bevacizumab and 1 week trapidil (n ¼ 7); Group IV, controln Trademark: Avastin® (Roche, Basel, Switzerland).
† Trademark: Rocarnal® (Rentschler-UCBGmbH, Kerpen, Germany).
Fig. 1. The bursting pressures of the groups. CI ¼ conﬁdence interval.
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tracheal transection and primary anastomoses with 7/0 vicryl
(Ethicon, Inc, Somerville, New Jersey). Animals were anesthetized
with 50 mg/kg intramuscular ketamine hydrochloride.z Vertical
neck incision was performed and the trachea was exposed with
microsurgical dissection. After careful hemostasis, transection was
done between the ﬁfth and sixth tracheal rings with microscissors.
Then, the rings were immediately anastomosed with 7/0 vicryl
under an operating microscope. During the procedure, suction was
performed, if needed, to avoid any aspiration of secretion and
blood. The neck was sutured under sterile conditions.
Anastomotic healing was assessed by measurement of bursting
pressure and inﬂammation score at the anostomotic region on the
seventh day. After transection of the trachea, a silastic catheter was
inserted into the proximal side of trachea. The distal end was ﬁxed
to a pressure transducer and saline was infused through the
catheter using a syringe pump at a rate of 2 mL/min. The pressure
was monitored with Biopac MP-100 Acquisition System (Biopak
Systems Inc, Goleta, California). Peak pressures documented ﬁrst
before rupture were recorded as the anastomotic bursting
pressures.
The anastomotic horizontally oriented specimens were ﬁxed in
10% formalin solution and embedded in paraﬁn. Hematoxylen-
eosin stained 4 μm-thick sections were evaluated for each case and
also specimens were stained using Masson’s trichrome for detect-
ing ﬁbrosis. Among items for anastomotic healing inﬂammation,
ﬁbrosis and epithelial regeneration were semiquatitatively scored
in the intercarilaginous area. The inﬂammation, ﬁbrosis, and
epithelial integrity were evaluated according to the modiﬁed Hyun
Sung et al5 numerical scale. Fibrosis was graded between 1 and 3,
where Grade 1 ¼ indicates no ﬁbrosis, Grade 2 ¼ moderate
ﬁbrosis, and Grade 3 ¼ widespread ﬁbrosis. The inﬂammation,
including lymphocytes and neutrophils, were graded as Grade 1 ¼
indicating no inﬂammatory cells, Grade 2 ¼ mild, Grade 3 ¼
moderate, and Grade 4 ¼ severe inﬂamation. Epithelial integrity,
deﬁned as the mucosal lining of the epithelium above the
inﬂamation as the percentage of the mucosal lining of the
epithelium (0%–100%), was semiquantitatively evaluated. All speci-
mens were histopathologically detected with a Nikon Eclipse 80i
bright ﬁeld microscope (Nikon Instruments Inc, Melville,
New York).
Data were represented as mean (SEM). Mann-Whitney U test
was used for comparison of bursting pressures. P values o 0.05
were considered statistically signiﬁcant.Results
All animals survived the tracheal anastomoses procedure. No
complication was observed. The bursting pressures of Group II,
Group III, and Group V were signiﬁcantly higher than the controls
(P ¼ 0.001, P ¼ 0.033, and P ¼ 0.035, respectively). The bursting
pressure of Group I (bevacizumab group) was not different from
the control group (P ¼ 0.99). Because we are interested in wound
healing the comparison should be made with the sham group
instead of the control group. The bursting pressure of bevacizumab
wass less than in the sham group and it could be assumed
marginally signiﬁcant (P ¼ 0.073). Although the bursting pressure
of sham group was signiﬁcantly higher than controls (P ¼ 0.035)
there was no difference when compared with other groups
(P ¼ 0.62, Group II; P ¼ 1.0, Group III) (Figure 1). The bursting
pressure of the trapidil group was higher than that of the
bevacizumab group (P ¼ 0.002).z Trademark: Ketalar® (Eczacibasi-WL, Istanbul, Turkey).There was a signiﬁcant difference between Group I, Group II,
Group III, and Group IV when compared with the sham group
regarding the inﬂammation score for ﬁbrosis (Figure 2). However,
there were no differences between the groups with respect to
neutrophils, lymphocytes inﬁltration, and epithelial integrity.Discussion
Our study revealed that bevacizumab, which impairs blood
vessel growth, may interfere with wound repair and trapidil has a
considerable healing effect on tracheal anastomoses. To the best of
our knowledge, ours is the ﬁrst study investigating bevacizumab in
tracheal bursting pressure after tracheal transection in the English-
language literature.
Although bevacizumab did not seem to impair anastomotic
healing at the administered dose compared with the control
animals, this is not the case if compared with the sham group.
Intercartilaginous tissue is very thin and delicate in normal
trachea. However, postoperative healing tissue formed at the
end of the ﬁrst week is thicker macroscopically and is histolog-
ically shown to have dense ﬁbrous architecture. Therefore, it
seems more logical to compare all the groups to sham-operated
animals instead of the controls. Lower bursting pressure of the
bevacizumab group compared with sham animals may be
interpreted as impairment of wound healing. Although the
bursting pressure of the sham group was higher than the
bevacizumab group it did not reach statistical signiﬁcance
(P ¼ 0.073). Trapidil increased the impaired bursting pressure
of bevacizumab application. Histologic ﬁndings also contribute
to this phenomenon.
Angiogenesis is a necessary step in wound healing. Nitric oxide
is an important mediator in the angiogenesis. Bevacizumab can
cause delayed or abnormal wound healing, wound dehiscence and
hemorrhage. Bevacizumab inhibits nitric oxide synthase. Although
we did not measure the nitric oxide level, it has been reported that
inhibition of nitric oxide synthesis has deleterious effects on
tracheal anastomotic healing.6 Bevacizumab in serum has a half-
life of 20 days. Bronchogenic carcinoma involving the carina or
tracheobronchial angle needs special surgical technique and air-
way management. Neoadjuvant combination of chemotherapy and
bevacizumab is 1 of the strategies that can be used in these
Fig. 2. (A) Horizontal-section of tracheal anastomoses in a control rat (hematoxylin and eosin stain  100). The histopathologic examination demonstrated the surface
epithelium (black arrow), mild inﬂammation, and no ﬁbrosis (white arrow) in the intercartilaginous area. (B) Horizontal-section of tracheal anastomoses in a control rat
(trichrome stain  100). No ﬁbrosis is visible in the intercartilaginous area. (C) Horizontal-section of tracheal anastomoses in a sham rat (hematoxylin and eosin stain 
100). Histopathologic examination revealed slauthing epithelium (white arrow), moderate inﬂammation, and severe ﬁbrosis (white arrow) in the intercartilaginous area.
(D) Horizontal-section of tracheal anastomoses in a sham rat (trichrome stain  100). Histopathologic examination revealed multilayered surface epithelium (white arrow)
as swell as intense and widespread ﬁbrosis (black arrow) in the intercartilaginous area.
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eration the time of operation for wound healing among patients
with bronchogenic carcinoma treated with bevacizumab. The
upper airways and bronchial walls have similar histologies.
Because it is difﬁcult to make anastomoses in the bronchial tree
of rats we investigated the effect of bevacizumab and trapidil on
wound healing after tracheal transection.
Trapidil has various properties, including vasodilation, reduc-
tion of the inﬂammatory response to injury, inhibition of lipid
peroxidation, and platelet aggregation. It has been reported that
trapidil may improve wound healing in colonic and tracheal
anastomoses in rats.4,9 These results are consistent with ours.Conclusions
Although bevacizumab seems to impair anastomotic healing,
trapidil can be suggested to impove the tracheal anastomoses after
the transection process. Further studies are needed to address the
exact mechanisms of this result.Acknowledgments
The authors thank Dr. Arzu Kanik of Mersin University for
statistical analysis and graphic representation assistance. All
authors contributed equally to the creation of this manuscript.Conﬂicts of Interest
The authors have indicated that they have no conﬂicts of
interest regarding the content of this article.
References
[1] Pectasides D, Papaxoinis G, Kalogeras K, et al. XELIRI-bevacizumab versus
FOLFIRI-bevacizumab as ﬁrst-line treatment in patients with metastatic color-
ectal cancer: a Hellenic Cooperative Oncology Group Phase II trial with
collateral biomarker analysis. BMC Cancer. 2012;12:271.
[2] Leon L, Vazquez S, Gracia JM, et al. First-line bevacizumab, cisplatin and
vinorelbine plus maintenance bevacizumab in advanced non-squamous non-
small cell lung cancer chemo-naive patients. Exper Opin Pharmacother.
2012;13:1389–1396.
[3] Kamba T, McDonald DM. Mechanisms of advers effects of anti-VEGF therapy for
cancer. Br J Cancer. 2007;96:1788–1795.
[4] Polat G, Talas DU, Polat A, et al. Effects of triazolopyrimidine on lipid
peroxidation and nitric oxide levels in the corticosteroid-impaired healing of
rat tracheal anastomoses. Cell Biochem Funct. 2005;23:39–45.
[5] Hyun Sung S, Warnock M, Fang KC, et al. A comparison of rat tracheal transplant
models: implantation verses anastomotic techniques for the study of airway
rejection. Transplantation. 2002;73:695–700.
[6] Talas DU, Nayci A, Polat G, et al. The effects of dexamethasone on lipid
peroxidation and nitric oxide levels on the healing of tracheal anastomoses:
an experimental study in rats. Pharmacol Res. 2002;46:265–271.
[7] Dienstmann R, Markman B, Tabemero J. Application of monoclonal antibodies
as cancer therapy in solid tumors. Curr Clin Pharmacol. 2012;7:137–145.
[8] Lee SM, Baas P, Wakelee H. Anti-angiogenesis drugs in lung cancer. Respirology.
2010;15:387–392.
[9] Colak T, Nayci A, Polat G, et al. Effects of trapidil on the healing of colonic
anastomoses in an experimental rat model. ANZ J Surg. 2003;73:916–921.
